# CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients

> **NCT03571360** · PHASE2 · UNKNOWN · sponsor: **Medical University of Vienna** · enrollment: 42 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **OTHER:** PD-L1 positive vs PD-L1 negative NSCLC patients

## Key facts

- **NCT ID:** NCT03571360
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-10
- **Primary completion:** 2021-01-14
- **Final completion:** 2021-07-14
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2020-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03571360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03571360, "CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03571360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*